CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-10 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −16,167 | $110.38 | $1.8M | 0 |
| 2026-08-10 | Veness Adam M SVP, General Counsel and Sec. | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,167 | 60,000 | ||
| 2026-08-10 | Read Simon Director | Option exercise 10b5-1 | +2,777 | $18.36 | $51K | 2,777 |
| 2026-08-10 | Read Simon Director | Sale 10b5-1 | −70 | $107.11 | $7K | 2,707 |
| 2026-08-10 | Read Simon Director | Sale 10b5-1 | −737 | $108.17 | $80K | 1,970 |
| 2026-08-10 | Read Simon Director | Sale 10b5-1 | −831 | $108.95 | $91K | 1,139 |
| 2026-08-10 | Read Simon Director | Sale 10b5-1 | −272 | $109.96 | $30K | 867 |
| 2026-08-10 | Read Simon Director | Sale 10b5-1 | −470 | $111.05 | $52K | 397 |
| 2026-08-10 | Read Simon Director | Sale 10b5-1 | −397 | $111.77 | $44K | 0 |
| 2026-08-10 | Read Simon Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,777 | 22,223 | ||
| 2026-08-07 | Veness Adam M SVP, General Counsel and Sec. | Option exercise 10b5-1 | +3,833 | $17.88 | $69K | 3,833 |
| 2026-08-07 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −3,217 | $110.61 | $356K | 616 |
| 2026-08-07 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −616 | $111.18 | $68K | 0 |
| 2026-08-07 | Veness Adam M SVP, General Counsel and Sec. | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,833 | 76,167 | ||
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Option exercise 10b5-1 | +40,000 | $8.44 | $338K | 105,292 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Option exercise 10b5-1 | +126,000 | $8.44 | $1.1M | 231,292 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −10,384 | $107.49 | $1.1M | 220,908 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −23,907 | $108.05 | $2.6M | 197,001 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −2,373 | $109.10 | $259K | 194,628 |
| 2026-08-07 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −2,536 | $110.02 | $279K | 192,092 |
Page 4 of 24 · 470 trades